Company Overview of EPIRUS Biopharmaceuticals, Inc.
EPIRUS Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company’s pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment ...
699 Boylston Street
Boston, MA 02116
Key Executives for EPIRUS Biopharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $428.1K
Chief Financial Officer, Senior Vice President and Treasurer
Total Annual Compensation: $292.7K
Chief Technical Officer and Senior Vice President
Total Annual Compensation: $294.2K
Compensation as of Fiscal Year 2014.
EPIRUS Biopharmaceuticals, Inc. Key Developments
EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 7 15
EPIRUS Biopharmaceuticals, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues of $45,000. Loss from operations was $15,013,000 compared with $8,948,000 for the same period a year ago. Net loss was $15,286,000 or $0.65 per basic and diluted share compared with $9,890,000 or $28.71 per basic and diluted share for the same period a year ago.
For the six months, the company reported revenues of $70,000. Loss from operations was $22,235,000 compared with $15,170,000 for the same period a year ago. Net loss was $22,807,000 or $1.07 per basic and diluted share compared with $17,510,000 or $57.54 per basic and diluted share for the same period a year ago.
Epirus Biopharmaceuticals Signs Multi-Product, Multi-Region Profit-Sharing Collaboration with Polpharma Group
Jul 14 15
Epirus Biopharmaceuticals announced that it has signed a multi-product, multi-region profit-sharing collaboration with Polpharma Group, for select Epirus biosimilars.
The biosimilars covered in the collaboration include BOW015 (infliximab, reference biologic Remicade), BOW050 (adalimumab, reference biologic Humira) and BOW070 (tocilizumab, reference biologic Actemra), which represents $6 billion in innovator sales in the specified territories. With Epirus leading the global product development and clinical programs, both parties will jointly fund clinical development and collaborate on regulatory filings in the specified territories. Epirus will also be responsible for process development, scale-up and manufacturing, with Polpharma Group overseeing commercialization across the territories. Clinical development costs and eventual operating profit will be split 51% Polpharma Group and 49% Epirus. Polpharma Group will contribute about $30 million towards clinical development costs, as well as cover product launch costs across all three programs. Epirus retains the commercial rights to Switzerland and Norway along with select EU countries including Austria, Belgium, Denmark, Finland, Luxembourg, the Netherlands and Sweden, allowing the company to build its direct commercial footprint. Epirus also retains rights to North America and other global markets not addressed in this agreement. A joint management board will oversee the collaboration.
EPIRUS Biopharmaceuticals, Inc. - Special Call
Jul 14 15
To discuss a multi-product, multi-region profit-sharing collaboration for select EPIRUS biosimilars, including BOW015 (infliximab, reference biologic Remicade), BOW050 (adalimumab, reference biologic Humira) and BOW070 (tocilizumab, reference biologic Actemra)
Similar Private Companies By Industry
Recent Private Companies Transactions
September 30, 2014